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Background
In the Phase III, randomised, open-label ODIN trial,
treatment-experienced HIV-1-infected adults with no
screening DRV resistance-associated mutations received
DRV/r 800/100mg qd or DRV/r 600/100mg bid (both
arms + ≥2 NRTIs). At Week 48, 72.1% qd vs 70.9% bid
patients achieved HIV-1 RNA <50 copies/mL (95% CI =
-6.1 to 8.5%, p<0.001; ITT-TLOVR), confirming non-
inferiority of DRV/r qd. The relationship between DRV
PK and efficacy and safety following treatment with
DRV/r is explored.
Methods
Sparse blood sampling for PK evaluations was taken at
Weeks 4, 8, 24 and 48 to determine DRV trough con-
centrations (C0h) and exposure (AUC24h, calculated as
AUC12h x 2 for bid) using a population pharmacokinetic
model. Relationships between PK parameters and effi-
cacy (change in log10 HIV-1 RNA and virological
response [HIV-1 RNA <50 copies/mL]) were assessed
using ANCOVAs. Relationships between PK parameters
and occurrence of adverse events of interest and labora-
tory lipid abnormalities were evaluated using descriptive
statistics.
Results
PK data were available for 280 DRV/r qd patients and
278 bid patients. Median (range) C0h was 1896 (184-
7881) ng/mL for DRV/r qd and 3197 (250-11,865) ng/mL
for DRV/r bid. Median (range) AUC24h for DRV/r qd was
87,788 (45,456-236,920) ng.h/mL and 109,401 (48,934–
323,820) ng.h/mL for bid. No relevant relationships were
observed between DRV PK and efficacy: changes from
baseline in HIV-1 RNA log10 copies/mL at Week 48 for
pooled data by DRV AUC24h quartile ranges (≤79,576;
79,577-100,376; 100,377-119,356; >119,356 ng.h/mL)
were -2.06, -2.22, -2.19, and -2.08 log10 copies/mL,
respectively. The % patients achieving HIV-1 RNA <50
copies/mL by these quartile ranges were 82.0%, 88.5%,
82.6% and 76.5% (observed data), respectively. In a logis-
tic regression analysis adjusting for baseline viral load,
AAG levels and number of sensitive NRTIs in the opti-
mised background regimen, there were no relevant rela-
tionships between PK and virological response. No
apparent relationships were observed between DRV PK
and occurrence of rash-, cardiac-, GI-, liver-, lipid- and
glucose-related AEs or laboratory lipid abnormalities.
Conclusions
Dosing with DRV/r 800/100mg qd resulted in lower C0h
and AUC24h compared to DRV/r 600/100mg bid; how-
ever, comparable efficacy between DRV/r qd and bid
confirmed adequate DRV concentrations were achieved
following qd dosing. No relevant relationships were
observed between DRV PK and efficacy or safety at
Week 48.
Author details
1Tibotec Inc, Titusville, NJ, USA. 2Tibotec BVBA, Beerse, Belgium.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P185
Cite this article as: Sekar et al.: Pharmacokinetic (PK) and
pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir
(DRV/r) in the ODIN trial. Journal of the International AIDS Society 2010 13
(Suppl 4):P185.1Tibotec Inc, Titusville, NJ, USA
Full list of author information is available at the end of the article
Sekar et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P185
http://www.jiasociety.org/content/13/S4/P185
© 2010 Sekar et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
